Sanofi Pasteur, the vaccines global business unit of Sanofi, has entered into an agreement with the U.S. Department of Health and Human Services (HHS) to increase the company’s domestic pandemic influenza vaccine production capabilities in Swiftwater, PA. The contract is supported by federal funds from the Biomedical Advance Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response at HHS.

The contract will support the clinical development and manufacturing of an adjuvanted recombinant pandemic vaccine to help enhance U.S. and global pandemic preparedness.  This investigational pandemic vaccine will utilize the same recombinant technology as Sanofi’s Flublok Quadrivalent. In addition, the contract will expand the site’s role as a center of excellence for pandemic preparedness by adding both recombinant and adjuvant manufacturing alongside current egg-based manufacturing.

“We are pleased to be taking this critical next step in our longstanding relationship with BARDA, which will enable us to significantly enhance flu vaccine supply under pandemic influenza scenarios,” said David Loew, executive vice president, Vaccines at Sanofi. “We are deeply committed to advancing influenza vaccine technology and manufacturing, and our public and private partnerships are an important part of these ongoing efforts to help protect people from influenza.”

Flublok Quadrivalent is indicated for adults 18 years of age and older and proven in a randomized controlled trial to help prevent 30 to 43 percent more cases of laboratory-confirmed influenza in people 50 years of age and older compared to a standard-dose quadrivalent inactivated influenza vaccine. Flublok Quadrivalent is the only recombinant protein-based influenza vaccine approved by the U.S. FDA, providing an exact genetic match of hemagglutinin (HA) from each recommended vaccine virus. HA is the protein identified as key to stimulating immunity to influenza.